ESMO: AstraZeneca believes latest data 'validate' going it alone on next-gen ADCs

AstraZeneca presented promising Phase 1/2a data at ESMO for its in-house antibody-drug conjugate (ADC), AZD5335, showing overall response rates up to 56.1% in platinum-resistant ovarian cancer patients and a manageable safety profile. This validates the company's significant investment in its proprietary ADC platform, reinforcing its strategy to build an internal pipeline to compete in the growing ADC market and potentially displace chemotherapy, distinguishing it from peers relying on M&A for such assets.

Analysis

AstraZeneca presented encouraging Phase 1/2a data for its proprietary antibody-drug conjugate (ADC), AZD5335, at ESMO 2025, targeting platinum-resistant ovarian cancer. The study involving 189 patients demonstrated a 56.2% rate of no cancer worsening at a median 7.8 months follow-up across tested dose ranges. Overall response rates were notably high, reaching 56.1% at the 2-mg/kg dose, which validates the company's internal platform.

This data underscores AstraZeneca's strategic shift towards significant in-house investment in its ADC pipeline, moving beyond its successful collaborations like Enhertu and Datroway. The company is leveraging its own linker and topoisomerase I payload technologies, aiming to build a proprietary portfolio of seven ADCs. This approach differentiates AstraZeneca from competitors who often rely on M&A or licensing for ADC assets, highlighting its commitment to internal innovation and intellectual property.

While neutropenia was observed as the most common treatment-related adverse event, impacting 45.9% of patients at the highest 2.4-mg/kg dose, the safety profile was described as "very reassuring" at lower doses (1.6-2 mg/kg) with no unexpected toxicities. This manageable safety, combined with strong efficacy, positions AZD5335 as a promising candidate and reinforces AstraZeneca's thesis that ADCs can potentially displace traditional chemotherapy in certain indications, bolstering its long-term oncology pipeline.

Key Decisions for Investors

• Investors should closely monitor the clinical progression of AZD5335 and AstraZeneca's broader in-house ADC pipeline, as successful advancement could significantly enhance long-term growth prospects.
• Evaluate AstraZeneca's competitive positioning in the rapidly evolving ADC market, considering its differentiated strategy of internal platform development versus M&A-driven peers.
• The promising early data and strategic investment reinforce AstraZeneca's long-term oncology leadership, suggesting potential for sustained revenue growth from its proprietary ADC assets.